Photo from wikipedia
Checkpoint inhibitor (CPI) therapy has significantly improved overall survival in several cancers including metastatic melanoma (MM) and in the adjuvant setting. Cutaneous immune‐related adverse events (irAEs) secondary to CPIs are… Click to show full abstract
Checkpoint inhibitor (CPI) therapy has significantly improved overall survival in several cancers including metastatic melanoma (MM) and in the adjuvant setting. Cutaneous immune‐related adverse events (irAEs) secondary to CPIs are commonly observed; however, autoimmune blistering disorders such as bullous pemphigoid (BP) are rare.
Keywords:
checkpoint inhibitor;
cutaneous immune;
immune related;
related adverse;
adverse events
Journal Title: British Journal of Dermatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Dermatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!